CLINICAL TRIALS PROFILE FOR ZANTAC 25

505(b)(2) Clinical Trials for ZANTAC 25

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
OTC	NCT00443963 ↗	Total Antioxidant Effects of Esomeprazole in Dyspeptic Patients Receiving Non-steroidal Anti-inflammatory Drugs	Withdrawn	AstraZeneca	Phase 4	2006-12-01	The principal investigator hypothesizes that participants receiving NSAID drugs with dyspeptic symptoms have increased production of gastric levels of free radicals. The primary objective of the study is to determine if Esomeprazole Magnesium increases gastric total antioxidant capacity and decreases gastric free radical production in humans. Participants (age 18 years and older) with no history of upper GI bleeding who are receiving non-steroidal anti-inflammatory drugs and then develop dyspepsia will be recruited from our primary care clinic in Washington, DC. All eligible participants will undergo biopsies of antrum and corpus. The participants will be randomized to receive either Zantac OTC or Nexium for 15 days. On day 15, all participants will undergo repeat upper endoscopy to obtain biopsies of antrum and corpus. Tissue samples will then be extracted to determine total antioxidant capacity and lipid peroxide levels (as an indirect marker of free radical production).
OTC	NCT00443963 ↗	Total Antioxidant Effects of Esomeprazole in Dyspeptic Patients Receiving Non-steroidal Anti-inflammatory Drugs	Withdrawn	Medstar Health Research Institute	Phase 4	2006-12-01	The principal investigator hypothesizes that participants receiving NSAID drugs with dyspeptic symptoms have increased production of gastric levels of free radicals. The primary objective of the study is to determine if Esomeprazole Magnesium increases gastric total antioxidant capacity and decreases gastric free radical production in humans. Participants (age 18 years and older) with no history of upper GI bleeding who are receiving non-steroidal anti-inflammatory drugs and then develop dyspepsia will be recruited from our primary care clinic in Washington, DC. All eligible participants will undergo biopsies of antrum and corpus. The participants will be randomized to receive either Zantac OTC or Nexium for 15 days. On day 15, all participants will undergo repeat upper endoscopy to obtain biopsies of antrum and corpus. Tissue samples will then be extracted to determine total antioxidant capacity and lipid peroxide levels (as an indirect marker of free radical production).
OTC	NCT03145012 ↗	Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity	Unknown status	Dalhousie University	Phase 4	2018-05-01	The immune response against tumors can be highly effective in preventing tumor development, growth and metastasis under certain circumstances. However, tumor associated immune suppression can profoundly limit the impact of natural tumor immunity and also reduce the effectiveness of tumor immunotherapy strategies. A major component of tumor associated immune suppression is mediated by myeloid cells, especially the monocytic subset of myeloid derived suppressor cells (MDSC). In recent studies that were conducted through a CCSRI Innovation grant, the investigators discovered that oral treatment of mice with the commonly used histamine receptor 2 (H2) antagonists ranitidine or famotidine inhibits both primary breast tumor development and metastasis, in three distinct mouse tumor models and reduces the numbers of monocytic MDSC. These findings have enormous potential to aid in effective cancer immunotherapy and may have immediate implications for cancer patients. The objective of this investigation is to determine whether treatment with the H2 receptor antagonist ranitidine alters immune suppression, through modulation of immune cell populations. The investigators will examine peripheral blood monocyte, neutrophil and NK cell numbers, subsets and activation status from healthy volunteers treated for 6 weeks with daily oral ranitidine. Ranitidine is widely available and used over the counter in Canada. These drugs are widely recognized as safe, well tolerated and have very few side effects. It has been suggested that among the general population, over 10% of those over the age of 65 take such medications on a regular basis for relief against gastrointestinal discomfort. The outcome of pre-clinical studies in mice warrant further investigation into transferability to humans. If the outcome of the current proposal proves to be viable, then these drugs could provide a safe method to reduce tumor associated immunosuppression with broad implications, both for current cancer patients and for those at high risk of developing cancer. Further to this, the outcome of our proposal may provide a new strategy for improving the effectiveness of T-cell mediated immunotherapy.
OTC	NCT03145012 ↗	Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity	Unknown status	Nova Scotia Health Authority	Phase 4	2018-05-01	The immune response against tumors can be highly effective in preventing tumor development, growth and metastasis under certain circumstances. However, tumor associated immune suppression can profoundly limit the impact of natural tumor immunity and also reduce the effectiveness of tumor immunotherapy strategies. A major component of tumor associated immune suppression is mediated by myeloid cells, especially the monocytic subset of myeloid derived suppressor cells (MDSC). In recent studies that were conducted through a CCSRI Innovation grant, the investigators discovered that oral treatment of mice with the commonly used histamine receptor 2 (H2) antagonists ranitidine or famotidine inhibits both primary breast tumor development and metastasis, in three distinct mouse tumor models and reduces the numbers of monocytic MDSC. These findings have enormous potential to aid in effective cancer immunotherapy and may have immediate implications for cancer patients. The objective of this investigation is to determine whether treatment with the H2 receptor antagonist ranitidine alters immune suppression, through modulation of immune cell populations. The investigators will examine peripheral blood monocyte, neutrophil and NK cell numbers, subsets and activation status from healthy volunteers treated for 6 weeks with daily oral ranitidine. Ranitidine is widely available and used over the counter in Canada. These drugs are widely recognized as safe, well tolerated and have very few side effects. It has been suggested that among the general population, over 10% of those over the age of 65 take such medications on a regular basis for relief against gastrointestinal discomfort. The outcome of pre-clinical studies in mice warrant further investigation into transferability to humans. If the outcome of the current proposal proves to be viable, then these drugs could provide a safe method to reduce tumor associated immunosuppression with broad implications, both for current cancer patients and for those at high risk of developing cancer. Further to this, the outcome of our proposal may provide a new strategy for improving the effectiveness of T-cell mediated immunotherapy.
OTC	NCT03145012 ↗	Histamine Receptor 2 Antagonists as Enhancers of Anti-Tumour Immunity	Unknown status	Lisa Barrett	Phase 4	2018-05-01	The immune response against tumors can be highly effective in preventing tumor development, growth and metastasis under certain circumstances. However, tumor associated immune suppression can profoundly limit the impact of natural tumor immunity and also reduce the effectiveness of tumor immunotherapy strategies. A major component of tumor associated immune suppression is mediated by myeloid cells, especially the monocytic subset of myeloid derived suppressor cells (MDSC). In recent studies that were conducted through a CCSRI Innovation grant, the investigators discovered that oral treatment of mice with the commonly used histamine receptor 2 (H2) antagonists ranitidine or famotidine inhibits both primary breast tumor development and metastasis, in three distinct mouse tumor models and reduces the numbers of monocytic MDSC. These findings have enormous potential to aid in effective cancer immunotherapy and may have immediate implications for cancer patients. The objective of this investigation is to determine whether treatment with the H2 receptor antagonist ranitidine alters immune suppression, through modulation of immune cell populations. The investigators will examine peripheral blood monocyte, neutrophil and NK cell numbers, subsets and activation status from healthy volunteers treated for 6 weeks with daily oral ranitidine. Ranitidine is widely available and used over the counter in Canada. These drugs are widely recognized as safe, well tolerated and have very few side effects. It has been suggested that among the general population, over 10% of those over the age of 65 take such medications on a regular basis for relief against gastrointestinal discomfort. The outcome of pre-clinical studies in mice warrant further investigation into transferability to humans. If the outcome of the current proposal proves to be viable, then these drugs could provide a safe method to reduce tumor associated immunosuppression with broad implications, both for current cancer patients and for those at high risk of developing cancer. Further to this, the outcome of our proposal may provide a new strategy for improving the effectiveness of T-cell mediated immunotherapy.
OTC	NCT04397445 ↗	Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration	Completed	Spaulding Clinical Research LLC	Phase 1	2020-06-08	Ranitidine is an over-the-counter and prescription drug, which decreases the amount of acid secreted by the stomach. Some ranitidine medicines contain an impurity called N-nitrosodimethylamine (NDMA) at low levels. NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables. The US Food and Drug Administration (FDA) has found levels of NDMA in some ranitidine products similar to the levels you would expect to be exposed to if you ate common foods like grilled or smoked meats. The ranitidine that will be used in this study has been tested twice (months apart) and shown to have stable NDMA levels well below the acceptable daily limit. Of note, the risk of NDMA with ranitidine is only relevant with prolonged chronic administration as at the acceptable limit, there is approximately a 1 in 100,000 chance of cancer after 70 years of exposure to that level. FDA has also conducted tests that simulate the potential formation of NDMA from ranitidine after it has been exposed to acid in the stomach with a normal diet. Results of these tests indicate that NDMA is not formed in typical stomach conditions. Similarly, if ranitidine is exposed to a simulated small intestinal fluid, NDMA is not formed. Other laboratory experiments suggest a combination of nitrites, such as found in processed meats, and an acidic environment may increase NDMA formation, however the levels of nitrites tested were very high. Separately, a previous study in 10 healthy volunteers showed that volunteers who received ranitidine had an increase in urinary NDMA excreted over 24 h. The level of increase was greater than would be expected from laboratory testing. This clinical study is being performed to determine if and how much NDMA is produced from ranitidine in the human body and whether nitrite-containing foods may increase formation of NDMA. The study will use a prescription dose of ranitidine (300 mg) to test whether there is increased urinary NDMA excretion levels over 24-hours after ranitidine administration in comparison to placebo when participants are administered low nitrite/NDMA meals and when subjects are administered high nitrite/NDMA meals. On 4 different days, each participant will receive ranitidine or placebo with high nitrite/NDMA meals and ranitidine or placebo with low nitrite/NDMA meals.
OTC	NCT04397445 ↗	Clinical Study to Investigate the Urinary Excretion of N-nitrosodimethylamine (NDMA) After Ranitidine Administration	Completed	Food and Drug Administration (FDA)	Phase 1	2020-06-08	Ranitidine is an over-the-counter and prescription drug, which decreases the amount of acid secreted by the stomach. Some ranitidine medicines contain an impurity called N-nitrosodimethylamine (NDMA) at low levels. NDMA is classified as a probable human carcinogen (a substance that could cause cancer) based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables. The US Food and Drug Administration (FDA) has found levels of NDMA in some ranitidine products similar to the levels you would expect to be exposed to if you ate common foods like grilled or smoked meats. The ranitidine that will be used in this study has been tested twice (months apart) and shown to have stable NDMA levels well below the acceptable daily limit. Of note, the risk of NDMA with ranitidine is only relevant with prolonged chronic administration as at the acceptable limit, there is approximately a 1 in 100,000 chance of cancer after 70 years of exposure to that level. FDA has also conducted tests that simulate the potential formation of NDMA from ranitidine after it has been exposed to acid in the stomach with a normal diet. Results of these tests indicate that NDMA is not formed in typical stomach conditions. Similarly, if ranitidine is exposed to a simulated small intestinal fluid, NDMA is not formed. Other laboratory experiments suggest a combination of nitrites, such as found in processed meats, and an acidic environment may increase NDMA formation, however the levels of nitrites tested were very high. Separately, a previous study in 10 healthy volunteers showed that volunteers who received ranitidine had an increase in urinary NDMA excreted over 24 h. The level of increase was greater than would be expected from laboratory testing. This clinical study is being performed to determine if and how much NDMA is produced from ranitidine in the human body and whether nitrite-containing foods may increase formation of NDMA. The study will use a prescription dose of ranitidine (300 mg) to test whether there is increased urinary NDMA excretion levels over 24-hours after ranitidine administration in comparison to placebo when participants are administered low nitrite/NDMA meals and when subjects are administered high nitrite/NDMA meals. On 4 different days, each participant will receive ranitidine or placebo with high nitrite/NDMA meals and ranitidine or placebo with low nitrite/NDMA meals.

All Clinical Trials for ZANTAC 25

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00030992 ↗	BMS 247550 to Treat Kidney Cancer	Completed	National Cancer Institute (NCI)	Phase 2	2002-02-01	This study will examine whether the experimental drug BMS 247550 (Ixabepilone) is an effective treatment for kidney cancer. BMS 247550 belongs to a class of drugs called epothilones that interfere with the ability of cancer cells to divide. In the way they kill cells, they are very similar to a class of compounds known as the taxanes, which include the drug Taxol. Other characteristics of the epothilones, however, enable them to work in cells that are resistant to Taxol. Patients 18 years of age or older with kidney cancer that has not spread to the central nervous system (unless the brain tumor has remained stable for at least six months after surgical or radiation treatment) may be eligible for this study. Pregnant or nursing women may not participate. Candidates are screened with various tests that may include blood and urine tests, electrocardiogram (EKG), and chest x-ray. Computerized tomography (CT) scans or X-rays, and possibly nuclear medicine studies may be done to determine the extent of disease. Participants receive BMS 247550 by a 1-hour infusion into a vein for 5 consecutive days (days 1, 2, 3, 4 and 5) of each 21-day treatment cycle. Patients must stay in the National Institutes of Health (NIH) area near Bethesda, Maryland, for 7 to 8 days during the first treatment cycle and for the 5 days of treatment in subsequent cycles. The total number of cycles will vary among patients, depending on their individual clinical situation. The drug dose may be increased gradually in subsequent cycles in patients who can tolerate such increases. In addition, participants undergo the following tests and procedures: - Periodic physical examinations and frequent blood tests - X-ray and other imaging studies to determine if the tumor is responding to the treatment. - Tumor biopsies to confirm the diagnosis or spread of tumor and to examine the reaction of certain proteins in cancer cells to BMS 247550. Two biopsies will be done. For this procedure, a small piece of tumor tissue is withdrawn through a needle under local anesthetic. Treatment will be stopped in patients whose tumor grows while receiving BMS 247550. Patients whose tumor disappears completely will be followed at NIH periodically for examinations and tests. Patients whose disease does not completely resolve or whose disease recurs may be advised of other appropriate research protocols at NIH or, if none are available, will be returned to the care of their local doctor.
NCT00223691 ↗	Treatment of Orthostatic Hypotension in Autonomic Failure	Completed	Vanderbilt University	Phase 1	2002-03-01	The autonomic nervous system serves multiple regulatory functions in the body, including the regulation of blood pressure and heart rate, gut motility, sweating and sexual function. There are several diseases characterized by abnormal function of the autonomic nervous system. Medications can also alter autonomic function. Impairment of the autonomic nervous system by diseases or drugs may lead to several symptoms, including blood pressure problems (e.g., high blood pressure lying down and low blood pressure on standing), sweating abnormalities, constipation or diarrhea and sexual dysfunction. Because treatment options for these patients are limited. We propose to study patients autonomic failure and low blood pressure upon standing and determine the cause of their disease by history and examination and their response to autonomic testing which have already been standardized in our laboratory. Based on their possible cause, we will tests different medications that may alleviate their symptoms.
NCT00223691 ↗	Treatment of Orthostatic Hypotension in Autonomic Failure	Completed	Vanderbilt University Medical Center	Phase 1	2002-03-01	The autonomic nervous system serves multiple regulatory functions in the body, including the regulation of blood pressure and heart rate, gut motility, sweating and sexual function. There are several diseases characterized by abnormal function of the autonomic nervous system. Medications can also alter autonomic function. Impairment of the autonomic nervous system by diseases or drugs may lead to several symptoms, including blood pressure problems (e.g., high blood pressure lying down and low blood pressure on standing), sweating abnormalities, constipation or diarrhea and sexual dysfunction. Because treatment options for these patients are limited. We propose to study patients autonomic failure and low blood pressure upon standing and determine the cause of their disease by history and examination and their response to autonomic testing which have already been standardized in our laboratory. Based on their possible cause, we will tests different medications that may alleviate their symptoms.
NCT00233935 ↗	Defined Green Tea Catechin Extract in Preventing Esophageal Cancer in Patients With Barrett's Esophagus	Completed	National Cancer Institute (NCI)	Phase 1	2005-11-01	The goal of this clinical research study is to test the safety of defined green tea catechin extract at different dose levels. Researchers also want to find out what effects, good and bad, it may have on individual and their risk for esophagus cancer. Esophagus cancer is an increased risk associated with Barrett's esophagus. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of defined green tea catechin extract may prevent esophageal cancer.
NCT00247130 ↗	Comparison of Intravenous Omeprazole to Ranitidine on Recurrent Bleeding After Endoscopic Treatment of Bleeding Ulcer	Withdrawn	Keio University	Phase 4	2005-10-01	The present study will compare the hemostasis-maintaining effects of intravenous omeprazole and ranitidine in patients with upper gastrointestinal hemorrhage that have undergone endoscopic hemostasis, to establish which anti-secretory medication prior to the start of oral alimentation is effective in preventing re-hemorrhage after hemostasis.
NCT00443963 ↗	Total Antioxidant Effects of Esomeprazole in Dyspeptic Patients Receiving Non-steroidal Anti-inflammatory Drugs	Withdrawn	AstraZeneca	Phase 4	2006-12-01	The principal investigator hypothesizes that participants receiving NSAID drugs with dyspeptic symptoms have increased production of gastric levels of free radicals. The primary objective of the study is to determine if Esomeprazole Magnesium increases gastric total antioxidant capacity and decreases gastric free radical production in humans. Participants (age 18 years and older) with no history of upper GI bleeding who are receiving non-steroidal anti-inflammatory drugs and then develop dyspepsia will be recruited from our primary care clinic in Washington, DC. All eligible participants will undergo biopsies of antrum and corpus. The participants will be randomized to receive either Zantac OTC or Nexium for 15 days. On day 15, all participants will undergo repeat upper endoscopy to obtain biopsies of antrum and corpus. Tissue samples will then be extracted to determine total antioxidant capacity and lipid peroxide levels (as an indirect marker of free radical production).
NCT00443963 ↗	Total Antioxidant Effects of Esomeprazole in Dyspeptic Patients Receiving Non-steroidal Anti-inflammatory Drugs	Withdrawn	Medstar Health Research Institute	Phase 4	2006-12-01	The principal investigator hypothesizes that participants receiving NSAID drugs with dyspeptic symptoms have increased production of gastric levels of free radicals. The primary objective of the study is to determine if Esomeprazole Magnesium increases gastric total antioxidant capacity and decreases gastric free radical production in humans. Participants (age 18 years and older) with no history of upper GI bleeding who are receiving non-steroidal anti-inflammatory drugs and then develop dyspepsia will be recruited from our primary care clinic in Washington, DC. All eligible participants will undergo biopsies of antrum and corpus. The participants will be randomized to receive either Zantac OTC or Nexium for 15 days. On day 15, all participants will undergo repeat upper endoscopy to obtain biopsies of antrum and corpus. Tissue samples will then be extracted to determine total antioxidant capacity and lipid peroxide levels (as an indirect marker of free radical production).

Clinical Trial Conditions for ZANTAC 25

Condition Name

Condition Name for ZANTAC 25
Intervention	Trials
NSAID Associated Gastric Ulcers	2
Healthy	2
Eustachian Tube Dysfunction	1
Spinal-induced Hypotension	1

Condition MeSH

Condition MeSH for ZANTAC 25
Intervention	Trials
Ulcer	3
Stomach Ulcer	2
Hypotension	2
Peritoneal Neoplasms	1

Clinical Trial Locations for ZANTAC 25

Trials by Country

Trials by Country for ZANTAC 25
Location	Trials
United States	12
Pakistan	2
Canada	2
Egypt	1
Japan	1

Trials by US State

Trials by US State for ZANTAC 25
Location	Trials
Maryland	3
Texas	2
Wisconsin	1
Utah	1
California	1

Clinical Trial Progress for ZANTAC 25

Clinical Trial Phase

Clinical Trial Phase for ZANTAC 25
Clinical Trial Phase	Trials
Phase 4	5
Phase 3	3
Phase 2	6

Clinical Trial Status

Clinical Trial Status for ZANTAC 25
Clinical Trial Phase	Trials
Completed	13
Withdrawn	4
Terminated	2

Clinical Trial Sponsors for ZANTAC 25

Sponsor Name

Sponsor Name for ZANTAC 25
Sponsor	Trials
National Cancer Institute (NCI)	3
AstraZeneca	3
Benazir Bhutto Hospital, Rawalpindi	2

Sponsor Type

Sponsor Type for ZANTAC 25
Sponsor	Trials
Other	18
Industry	7
NIH	4

Last updated: July 28, 2026

Zantac 25 (Ranitidine) Clinical Trials Update, Market Analysis, and Exclusivity/Generic Outlook

Zantac 25 is a low-dose form of ranitidine (H2-receptor antagonist). Commercial availability is constrained by global safety actions tied to N-nitrosodimethylamine (NDMA) formation concerns. Patent and exclusivity strategy is largely moot because FDA approval status for ranitidine products is effectively ended and many markets have withdrawn the product or restricted distribution. Clinical development activity is not directed to new approvals in major jurisdictions; the current landscape is dominated by post-withdrawal legacy supply and enforcement against re-marketing.

What does “Zantac 25” mean in regulatory terms?

Zantac 25 is a branded ranitidine product strength (25 mg). “Zantac” is not a new active or a new chemical entity; it is brand labeling for ranitidine.

What clinical trials are currently active for ranitidine?

No contemporary, regulator-facing, pivotal ranitidine trials are driving new NDA/BLA approvals in major markets after the NDMA-related actions. Clinical trial activity for ranitidine since the withdrawal era has shifted to:

• Analytical methods for NDMA and related impurities
• Stability, container/closure interaction, and process-science studies
• Retrospective pharmacovigilance and observational analyses

Because the commercial basis for continued ranitidine approvals has been structurally removed in key jurisdictions, the clinical-trial pipeline is not translating into new product registrations.

---

Are there any new ranitidine clinical trials that could restart approval?

Answer: Not in a way that would credibly restart approvals at scale in major regulators. The post-withdrawal ranitidine work is primarily chemistry, manufacturing, and controls (CMC) or analytical, not new therapeutic development.

What types of ranitidine studies remain?

Common remaining study categories include:

• NDMA impurity quantification and detection method validation
• Comparative impurity profiles under different manufacturing or storage conditions
• Degradation-pathway investigations relevant to N-nitrosamine control

Why do these trials not typically lead to new approvals?

The regulatory blocker is product safety for NDMA risk rather than a lack of efficacy evidence. Post-withdrawal studies can improve understanding and detection, but they do not create a new approval pathway absent an accepted risk mitigation and regulatory clearance for reintroduction.

---

What is the regulatory status of Zantac (ranitidine) in the US?

Answer: Ranitidine is no longer an FDA-approved product for marketing in the US after NDMA-related actions.

What actions changed the US market?

Key events included:

• FDA communications and recalls affecting multiple ranitidine products
• Broad withdrawal and removal from market channels
• An end-state where FDA approval for ranitidine products is effectively discontinued for routine marketing

(These actions drove the commercial collapse of ranitidine sales in the US and shifted the market to other H2 blockers and PPIs.)

---

What is the Orange Book status of Zantac 25 (ranitidine)?

Answer: Zantac 25 as a marketed ranitidine brand does not represent an active Orange Book exclusivity entry in the way ongoing small-molecule brand launches do. The Orange Book posture is functionally irrelevant to generic entry because the reference listed drug is not available for normal commercialization.

How does this affect generic strategy?

Even when patents exist, the generic business case requires an approved reference product and a viable regulatory pathway. With ranitidine’s withdrawal status in key markets, generics are typically blocked by:

• Absence of a functioning reference product for typical ANDA reliance
• Market authorization and safety clearance constraints independent of patent expiry

---

When does Zantac 25 lose exclusivity and when do patents expire?

Answer: The normal “exclusivity window to generic erosion” timeline is not the dominant driver for ranitidine. Safety-driven withdrawal determines market access.

What matters more than patent expiry?

• Regulatory clearance to market ranitidine again (if ever)
• NDMA risk acceptability for reintroduction, including CMC controls
• Enforcement and inspection outcomes tied to N-nitrosamine compliance

Practical implication for R&D and licensing

Patent expiry forecasting is low value for run-rate revenue planning for Zantac 25. The value is now tied to:

• Whether any jurisdiction permits ranitidine re-launch
• Whether an alternative H2 block with better safety perception captures residual demand

---

What patents protect ranitidine brands like Zantac 25?

Answer: Ranitidine’s core composition-of-matter and early formulation/processing IP has long since matured and largely expired or become non-operative as a market access constraint. The current risk is not patent litigation but regulatory authorization.

How patent estates typically look for older small molecules

For drugs like ranitidine, typical estates include:

• Composition and process patents from initial development decades earlier
• Narrow later-life patents for specific formulations or manufacturing methods

In practice, many of these have expired, and even active patents do not restore market access without regulatory approval.

---

Which companies are challenging ranitidine patents or seeking generic entry?

Answer: Generic challenge activity tied to ranitidine is not a prominent current driver because the product is not broadly marketed under FDA authorization. The main competitive set is therapeutic substitution, not ANDA-driven erosion.

Who competes with Zantac 25 today?

• Other H2 antagonists (where available)
• Proton pump inhibitors (PPIs) as the core replacement class

Competitive pressure is substitution at the prescribing and OTC shelf level rather than generic “Paragraph IV to brand” litigation.

---

What formulations are protected for ranitidine (Zantac 25)?

Answer: Formulation patents, where they exist, are not a business-critical barrier because ranitidine is not an actively expanding product line. Formulation IP has limited value without a viable regulatory authorization and supply chain.

What formulation angles would matter if re-launch were possible?

• NDMA control via specific excipient selection
• Stability under real-world storage conditions
• Manufacturing process parameters to minimize N-nitrosamines

These are CMC issues more than classic formulation IP barriers.

---

How does Zantac 25 compare with famotidine, cimetidine, and PPIs in market access risk?

Answer: The market access risk for ranitidine is higher due to NDMA-driven regulatory actions. Famotidine and other H2 antagonists are competing alternatives, and PPIs have entrenched use.

Business implication

Even if ranitidine patents were still enforceable, substitution reduces the economic relevance of enforcing them.

---

What generic entry risks exist for Zantac 25?

Answer: The dominant “entry risk” is regulatory status, not patent barriers. A generic entry scenario requires:

• Regulatory re-acceptance of ranitidine
• Manufacturing that meets NDMA limits and validation expectations
• A viable approval framework in target jurisdictions

Without that, generic erosion does not occur in normal patent-expiry timelines.

---

What is the revenue exposure of Zantac 25 and how should it be projected?

Answer: Near-term revenue projections for Zantac 25 are not viable as a growing market category in FDA-led markets due to withdrawal status. Forecasting should treat Zantac 25 as a legacy product with constrained availability rather than an ongoing branded growth engine.

Projection logic (what drives the curve)

• Regulatory access: primary determinant
• Residual channel inventory and historical demand: secondary
• Substitution: primary competitive dynamic after withdrawal

Base-case market trajectory

• US: no sustained re-expansion; any remaining sales are limited by authorization, supply, and distribution clearance
• EU and other jurisdictions: depends on local NDMA actions, recall scope, and re-authorization status for ranitidine products

Without explicit jurisdictional authorization to market, growth forecasts are structurally suppressed.

---

What litigation affects ranitidine (Zantac) and NDMA-related claims?

Answer: Litigation risk for ranitidine exists, but it is dominated by safety claims and product liability rather than classic “ANDA vs brand patent” disputes.

How that differs from patent litigation

• Patent litigation affects entry and exclusivity
• NDMA litigation affects brand viability, settlement costs, and supply continuity

For investment and licensing, the economic exposure is primarily tied to settlement and product withdrawal outcomes, not enforceable patent duration.

---

Key Takeaways

• Zantac 25 is ranitidine at 25 mg; it is not a distinct therapeutic asset.
• The market collapse is driven by NDMA-related regulatory actions, not by patent expiry timing.
• Contemporary clinical development is not positioned to restart major regulatory approvals; remaining studies are largely analytical and CMC-focused.
• Generic entry risk is effectively governed by regulatory authorization to market ranitidine, not by Orange Book exclusivity or Paragraph IV challenges.
• Competitive pressure comes from therapeutic substitution (other H2 antagonists and PPIs), reducing the relevance of an ANDA-style erosion model for Zantac 25.

---

FAQs

1. Can ranitidine be re-approved in the US after NDMA findings?
   Re-approval requires regulator-accepted NDMA risk control and CMC clearance; absent that, marketing remains constrained.

2. Do any active patents still block generic ranitidine products?
   Patent status is secondary to regulatory eligibility for marketing; where ranitidine is not authorized, patent barriers do not create a functional generic marketplace.

3. Are ranitidine recalls still ongoing for “Zantac” products globally?
   Recall scope is jurisdiction-specific; the global pattern in the withdrawal era has been largely dominated by NDMA risk controls.

4. What is the practical clinical replacement for Zantac 25?
   Treatment substitution typically shifts to other H2 antagonists and especially PPIs depending on indication.

5. What commercial channels can still sell Zantac 25 outside FDA markets?
   Sales depend on local authorization status, supply chain compliance, and whether local regulators permit continued marketing under NDMA controls.

---

References

1. U.S. Food and Drug Administration. (2019–2020). Drug safety communications and NDMA-related actions for ranitidine products. FDA.
2. European Medicines Agency. (2019–2020). Safety communications and measures regarding ranitidine and NDMA. EMA.
3. U.S. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (RLD records and ranitidine status). FDA.